A large-scale clinical trial conducted by the World Health Organization has determined that Gilead Sciences Inc.’s remdesivir had little or no effect on COVID-19 patients’ chances of survival or length of hospital stay. The antiviral drug had been granted Emergency Use Authorization (EUA) by the Food and Drug Administration in
As tenacious and pervasive as the coronavirus at the root of our long-running pandemic appears to be, SARS-CoV-2 has not only a host of strengths aiding its spread, but it also hides numerous vulnerabilities that could be exploited to help contain and defeat the deadly pathogen. Aside from lasting
Health officials in both Russia and around the world are raising concerns over Moscow’s approval of a vaccine to be used against the SARS-CoV-2 coronavirus, despite not having finished critical Phase 3 clinical trials for the new treatment necessary to determine both the effectiveness and safety of the new inoculation.
A new study suggests that children under five years of age may carry a much higher amount of the SARS-CoV-2 coronavirus in their upper respiratory tract than adults, with some children displaying a viral load up to 100 times greater than the adults tested for the presence of the coronavirus.